Subscribe

    Kara Mudd DMSc, PA-C: Use of Ruxolitinib in Pediatric Patients with Atopic Dermatitis

    Kara Mudd reviews findings from the Phase 3 TRuE-AD3 study evaluating topical ruxolitinib in children aged 2 to <12 years with atopic dermatitis. The discussion highlights how targeted JAK inhibition may offer an effective and well-tolerated treatment option for younger patients with mild to moderate disease.

    Topics Covered:

    • Overview of the TRuE-AD3 study design and pediatric population
    • Efficacy outcomes in children with atopic dermatitis
    • Safety profile of topical ruxolitinib in patients ages 2 to <12 years
    • Practical considerations for incorporating JAK inhibitors into pediatric care

     

    Explore Related Resources:

    MORE EXPERT PERSPECTIVES IN ATOPIC DERMATITIS

    Christopher Bunick, MD, PhD: Providing Rapid Itch Relief for Patients With Atopic Dermatitis

    Christopher Bunick, MD, PhD, an associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut, discusses a poster presentation comparing the itch

    PLAY
    George Han, MD, PhD: Advancing Atopic Dermatitis Care: Early Use of Topical JAK Inhibitors
    George Han, MD, PhD, discusses the evolving treatment strategies for patients with atopic dermatitis.
    PLAY
    Mona Shahriari, MD: Removal of Black Box Warnings Change Considerations for Hormonal Therapy in Atopic Dermatitis

    Dr. Shahriari reviews the FDA’s decision to remove certain “black box” warnings for hormone replacement therapy (HRT) and discusses how this shift may influence treatment

    PLAY
    Emma Guttman-Yassky, MD: Evaluating Long-term Efficacy of Upadacitinib in Patients with Atopic Dermatitis

    Dr. Johann Gudjonsson discusses how spesolimab may reduce low-grade inflammation between flares in patients with generalized pustular psoriasis (GPP). Topics Covered: Subclinical inflammation in GPP

    PLAY
    Lisa Swanson, MD: Topical Therapies for the Treatment of Atopic Dermatitis

    Dr. Lisa Swanson highlights three effective nonsteroidal topical therapies for managing atopic dermatitis in both pediatric and adult patients. Topics Covered: Nonsteroidal topical options for

    PLAY
    Raj Chovatiya, MD, PhD: Maintaining Optimal Treatment Targets with Upadacitinib for Patients with Atopic Dermatitis

    Dr. Raj Chovatiya presents long-term data on upadacitinib’s ability to maintain skin clearance and itch relief in atopic dermatitis patients over 140 weeks. Topics Covered:

    PLAY
    Diego Ruiz Dasilva, MD, FAAD: Investigating Combination Topical Ruxolitinib and Systemic Therapies for Atopic Dermatitis

    Dr. Diego Ruiz Dasilva reviews real-world data showing the safety and efficacy of combining topical ruxolitinib with systemic therapies in atopic dermatitis care. Topics Covered:

    PLAY
    Andrew Mastro, MS, PA-C: Managing the Psychosocial and Occupational Burden of Chronic Hand Eczema

    Andrew Mastro, MS, PA-C, addresses the psychosocial impact of chronic hand eczema and highlights emerging treatments like biologics and JAK inhibitors. Topics Covered: Quality of

    PLAY
    Andrew Mastro, MS, PA-C: Providing Effective Treatment for the Head-and-neck Area in Patients with Atopic Dermatitis

    Andrew Mastro, MS, PA-C, addresses the psychosocial impact of chronic hand eczema and highlights emerging treatments like biologics and JAK inhibitors. Topics Covered: Quality of

    PLAY
    Naiem T. Issa, MD, PhD: Mitigating Economic Impacts of Atopic Dermatitis through Effective Treatment

    Dr. Naiem Issa shares real-world evidence showing how ruxolitinib cream may reduce treatment costs and productivity loss in patients with atopic dermatitis. Topics Covered: Economic

    PLAY
    Diego Ruiz Dasilva, MD, FAAD: Achievement of Optimal Treatment Targets with Oral JAK Inhibition in Elderly Patients with Atopic Dermatitis

    Dr. Diego Ruiz Dasilva highlights real-world data showing oral JAK inhibitors can safely and effectively achieve treatment targets in elderly patients with AD. Topics Covered:

    PLAY
    Lisa Swanson, MD: Insights on Maximum-use of Ruxolitinib Cream in Pediatric Patients with Atopic Dermatitis

    Dr. Lisa Swanson shares insights on maximum-use data for ruxolitinib cream in children ages 2–11 with atopic dermatitis, highlighting safety and efficacy. Topics Covered: Ruxolitinib

    PLAY
    Lisa Swanson, MD: Insights on Maximum-use of Ruxolitinib Cream in Pediatric Patients with Atopic Dermatitis

    Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients

    PLAY
    Michael Cameron, MD, FAAD: Improving Itch and Quality of Life in Patients with Atopic Dermatitis

    Dr. Michael Cameron discusses 52-week results showing rapid and lasting improvements in itch and quality of life with upadacitinib plus topical steroids. Topics Covered: Combination

    PLAY
    James Song, MD: Personalizing Treatment for Atopic Dermatitis

    Dr. James Song highlights the need for personalized approaches in atopic dermatitis care to predict treatment response and reduce trial-and-error prescribing. Topics Covered: Personalization in

    PLAY
    James Song, MD, FAAD: Checking in on Long-term Safety Data on JAK Inhibitors for Atopic Dermatitis

    Dr. James Song reviews the latest long-term safety data on topical and oral JAK inhibitors for managing atopic dermatitis**.** Topics Covered: Long-term safety of JAK

    PLAY
    Melodie Young, MSN, RN, ANP-C: Treating Pediatric Patients with Atopic Dermatitis

    Melodie Young, MSN, RN, ANP-C, discusses treating young children with atopic dermatitis and counseling caregivers on potential side effects. Topics Covered: Pediatric atopic dermatitis treatment

    PLAY
    Melodie Young, MSN, RN, ANP-C: Practical Aspects of Treating Patients with Atopic Dermatitis
    Melodie Young discusses the logistics of gaining access to newer medications through speciality pharmacies for patients with atopic dermatitis.
    PLAY
    James Del Rosso, DO: Evaluating Effective Topical Therapies for Atopic Dermatitis
    Dr. Del Rosso discusses the current topical treatments available for patients with atopic dermatitis that have shown consistent efficacy with limited adverse events.
    PLAY
    Andrea Nguyen, PA-C, MS: Treatment Education for Patients with Atopic Dermatitis
    Andrea Nguyen, PA-C, MS, discusses how the internet and social media has contributed to more in-depth discussion with her patients regarding treatment for atopic dermatitis.
    PLAY
    Raj Chovatiya, MD, PhD: Atopic Dermatitis Patient Counseling for Moisturization
    Dr. Chovatiya discusses the effectiveness of providing a moisturizer in combination with a topical or systemic therapy to achieve clear skin regardless of disease severity.
    PLAY
    TJ Chao, PA-C: Considering Adverse Events in Patients with Atopic Dermatitis
    TJ Chao breaks down the black box warnings for ruxolitinib cream 1.5% and discusses the importance in communicating the specifics of these warnings to patients.
    PLAY
    Raj Chovatiya, MD: Key Ingredients in Moisturizers for Atopic Dermatitis
    Dr. Chovatiya reviews some of the essentials to look for in moisturizers such as a treatment that is semipermeable and has natural moisturizing factors.
    PLAY
    Raj Chovatiya, MD, PhD: Optimizing Atopic Dermatitis Treatment through Proper Moisturization
    Dr. Chovatiya discusses the benefits of a moisturization routine as a complement to all currently available therapies for patients with atopic dermatitis.
    PLAY
    TJ Chao, PA-C: Utilizing Topical Treatments for Patients with Atopic Dermatitis
    Mr. Chao discusses the reliability of ruxolitinib cream 1.5% in treating patients with atopic dermatitis. He emphasized how well it is tolerated by patients, as
    PLAY
    Matthew Zirwas, MD: Revolution of Topical Treatments in Atopic Dermatitis
    Dr. Matthew Zirwas reviews atopic dermatitis treatments that have been essential in providing immediate improvement in itch leading to a sense of control in his
    PLAY
    Jonathan I. Silverberg, MD, PhD, MPH, FAAD: Patient Counseling in Atopic Dermatitis
    Dr. Silverberg discusses how to safely counsel patients when deciding between topical versus oral JAK inhibitors for the treatment of atopic dermatitis.
    PLAY
    Peter Lio, MD, FAAD: Sustainable Improvements for Patients with Atopic Dermatitis
    Dr. Lio discusses the effects of topical ruxolitinib in his patients with atopic dermatitis, and how he incorporates this treatment into his practice.
    PLAY
    Adam Friedman, MD, FAAD: Matching Patients to the Right Treatments for Atopic Dermatitis​
    Dr. Friedman discusses how to evaluate patients with atopic dermatitis to match them with their best treatment as well as the importance of keeping a
    PLAY
    Raj Chovatiya, MD, PhD: Itch in Atopic Dermatitis
    Raj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, discusses
    PLAY
    Raj Chovatiya, MD, PhD: Explaining the Mechanisms and Advantages of JAK Inhibitors
    Raj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, discusses
    PLAY
    Peter Lio, MD: Innovations in JAK Inhibitors
    Peter Lio, MD, of Medical Dermatology Associates of Chicago in Chicago, Illinois, discusses recent innovations in atopic dermatitis therapies with regard to JAK inhibitors. Dr.
    PLAY

    JCAD

    Journal of Clinical and Aesthetic Dermatology

    Facebook-f X-twitter Instagram Linkedin Youtube Spotify

    ©2026 JCAD | The Journal of Clinical and Aesthetic Dermatology. All Rights Reserved.